secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041368
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q2 net loss $13.3M; orphan drug designation for TYRA-300 in achondroplasia
--------------------------------------------------------------------------------

- Net loss $13.3M vs $15.1M Q2 2022; cash & equivalents $232.4M as of June 30.
- FDA granted Orphan Drug Designation for TYRA-300 for achondroplasia in July 2023.
- SURF301 Phase 1/2 oncology study enrollment ongoing in Part A and Part B at U.S., EU, Australia sites.
- TYRA-200 Phase 1 study in intrahepatic cholangiocarcinoma on track to dose first patient 2H 2023.
- Strengthened leadership: appointed Dr. Michael Bober as VP Clinical Development and Medical Affairs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017023041368/0000950170-23-041368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017023041368/tyra-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer